Helix BioPharma Current Valuation vs. Cash Flow From Operations
| HBP Stock | CAD 0.79 0.05 5.95% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.69 | 0.68 |
|
|
For Helix BioPharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Helix BioPharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Helix BioPharma Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Helix BioPharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Helix BioPharma Corp over time as well as its relative position and ranking within its peers.
Helix |
Helix BioPharma Corp Cash Flow From Operations vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Helix BioPharma's current stock value. Our valuation model uses many indicators to compare Helix BioPharma value to that of its competitors to determine the firm's financial worth. Helix BioPharma Corp is rated # 4 in current valuation category among its peers. It is rated # 3 in cash flow from operations category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Helix BioPharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Helix BioPharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Helix Current Valuation vs. Competition
Helix BioPharma Corp is rated # 4 in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 456.27 Million. Helix BioPharma holds roughly 40.1 Million in current valuation claiming about 9% of equities under Health Care industry.
Helix Cash Flow From Operations vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Helix BioPharma |
| = | 40.1 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Helix BioPharma |
| = | (5.22 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Helix Cash Flow From Operations Comparison
Helix BioPharma is currently under evaluation in cash flow from operations category among its peers.
Helix BioPharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Helix BioPharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Helix BioPharma will eventually generate negative long term returns. The profitability progress is the general direction of Helix BioPharma's change in net profit over the period of time. It can combine multiple indicators of Helix BioPharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 5 M | 2.8 M | |
| Operating Income | -9.4 M | -9.8 M | |
| Income Before Tax | -9.4 M | -9.9 M | |
| Total Other Income Expense Net | -25 K | -26.2 K | |
| Net Loss | -9.3 M | -9.7 M | |
| Income Tax Expense | -132 K | -138.6 K | |
| Net Loss | -9.3 M | -9.7 M | |
| Net Loss | -7.2 M | -7.6 M | |
| Interest Income | 35.6 K | 37 K | |
| Net Interest Income | 24 K | 25.2 K | |
| Change To Netincome | 840.6 K | 882.6 K | |
| Net Loss | (0.21) | (0.22) | |
| Income Quality | 0.56 | 0.73 | |
| Net Income Per E B T | 1.13 | 1.03 |
Helix Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Helix BioPharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Helix BioPharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Helix BioPharma's important profitability drivers and their relationship over time.
Use Helix BioPharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.Helix BioPharma Pair Trading
Helix BioPharma Corp Pair Trading Analysis
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Helix BioPharma position
In addition to having Helix BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Compulsion Thematic Idea Now
Compulsion
Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. The Compulsion theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Compulsion Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Helix Stock
To fully project Helix BioPharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Helix BioPharma Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Helix BioPharma's income statement, its balance sheet, and the statement of cash flows.